Inhibitive effects of mifepristone on growth of breast cancer: Experiment with rats

National Medical Journal of China

Volumn 88, Issue 8, 2008, Pages 559-563

  Tian, Xing Song ^a   Zhou, Wen Hong ^b   Wu, Guo Jun ^b   Sun, Jing Zhong ^b   Cong, Ming Hua ^b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b NONE

Author keywords

Animal model; Athymic mouse; Breast cancer; Immunohistochemistry; Mifepristone

Indexed keywords

CD34 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MIFEPRISTONE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; VASCULOTROPIN; VEGETABLE OIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; BREAST CANCER; CANCER INHIBITION; CELL STRAIN MCF 7; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; FEMALE; IMMUNOHISTOCHEMISTRY; MICROSCOPY; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; RAT; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HORMONE ANTAGONISTS; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MIFEPRISTONE; NEOVASCULARIZATION, PATHOLOGIC; RANDOM ALLOCATION; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 43649105954     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Kettel LM. Clinical applications of the antiprogestins. Clin Obste Gynecol,1995,38:921-934.
2. Schneider MR, Michna H, Nishino Y, et al. Antitumor activity of the pro gesterone antagonists ZK 98.299 and RU38.486 in the hormone dependent MXT mammary tumor model of the mouse and the DMBA and the MNU induced mammary tumor model of the rat. Eur J Cancer Clin Oncol,1989,25:691-701.
3. Sartor O, Figg WD. Mifepristone: antineoplastic studies. Clin Obstet Gynecol,1996,39:498-505.
4. Marx J. Cell death studies yield cancer clues. Science,1993,259: 760-761.
5. Bhargava V, Kell DL, Van-de-Rijn M, et al. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol,1994,145:535-340.
6. Leek RD, Kaklamanis L, Pezzella Fc, et al. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumors and in situ cancer. BR J Cancer,1994,69:135-139.
7. Chinese source.
8. Linderhom BK, Lindh B, Beckman L, et al. Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. Clin Breast Cancer,2003,4:340-347.
9. Foekens JA, Peters HA, Grebenchtchikov N, et al. High tumor levels of vascular endothelial growth factor predict poor to response to systemic therapy in advanced breast cancer. Cancer Res,2001, 61:5407-5414.
10. Gasparini G, Weidner N, Bevilacqua P, et al. Tumor microvessel density, p53 expression, tumor size and peritumoral lymphatic invasion are relevant prognostic markers in node-negative breast cancer. Clin Oncol,1994,12:454.
11. Umekita Y, Takasaki T, Yoshida H. Expression of p53 protein in benign epithelial hyperplasia, a typical ductal hyperplasia, noninvasive and invasive mammary carcinoma: an immunohistochemical study. Virchows Archiv,1999,424:491.
12. Mullerat J, Deroide F, Winslet MC, et al. Proliferation and p53 expression in anal cancer precursor lesions. Anticancer Res,2003, 23:2995-2999.
13. Tut VM, Braithwaite AL, Angus B, et al. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, wafl,pRb and Ki67. Br J Cancer,2001,84:270-275.
14. Nakopoulou L, Stefanki K, Panayotopoulou E, et al. Expression of the vascular endothelial growth factor receptor-2/FIk-1 in breast carcinomas: correlation with proliferation. Hum Pathol,2002,33: 863-870.